{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Muniz P"],"pubmed_abstract":["Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) is an alternative option for patients who do not have an HLA-matched donor. The use of post-transplantation high dose cyclophosphamide (PT-Cy) is commonly employed for graft-versus-host disease (GVHD) prophylaxis in haplo-HSCT. Cyclophosphamide (Cy) is an alkylating agent with antineoplastic and immunosuppressive activity, whose bioactivation requires the activity of polymorphic enzymes in the liver to produce phosphoramide mustard, which is a DNA alkylating agent. To identify polymorphisms in the genes of Cy metabolism and correlate them with post-HSCT complications [GVHD, sinusoidal obstruction syndrome (SOS), hemorrhagic cysti"],"journal":["Frontiers in immunology"],"pagination":["1002959"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9537744"],"repository":["biostudies-literature"],"pubmed_title":["Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation."],"pmcid":["PMC9537744"],"pubmed_authors":["Muniz P","Dorado N","Kwon M","Bailen R","Martinez-Laperche C","Diez-Martin JL","Anguita J","Andres-Zayas C","Gallardo D","Gomez Centurion I","Carbonell D","Buno I","Chicano M","Suarez-Gonzalez J","Oarbeascoa G"],"additional_accession":[]},"is_claimable":false,"name":"Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.","description":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for patients with hematologic malignances. Haploidentical HSCT (Haplo-HSCT) is an alternative option for patients who do not have an HLA-matched donor. The use of post-transplantation high dose cyclophosphamide (PT-Cy) is commonly employed for graft-versus-host disease (GVHD) prophylaxis in haplo-HSCT. Cyclophosphamide (Cy) is an alkylating agent with antineoplastic and immunosuppressive activity, whose bioactivation requires the activity of polymorphic enzymes in the liver to produce phosphoramide mustard, which is a DNA alkylating agent. To identify polymorphisms in the genes of Cy metabolism and correlate them with post-HSCT complications [GVHD, sinusoidal obstruction syndrome (SOS), hemorrhagic cysti","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-31T16:06:04.69Z","creation":"2025-02-19T01:28:13.577Z"},"accession":"S-EPMC9537744","cross_references":{"pubmed":["36211438"],"doi":["10.3389/fimmu.2022.1002959"]}}